Kamada Enters Into US Distribution Agreement For Intravenous Alpha-1 Antitrypsin

Kamada has entered into an agreement with a US specialty pharmaceutical distributor company for the distribution of its product, intravenous alpha-1 antitrypsin (AAT-IV) in the US.

Under the terms of the agreement, the US company will be responsible for the product’s distribution and additional activities relating to sales and marketing.

However, Kamada will be responsible for the production and delivery of AAT-IV to the US company, following its approval by the FDA.

In order to maintain exclusivity of the distribution in the US, the US company will be required to purchase from Kamada minimum quantities of AAT-IV of at least $15m within the first eighteen months following approval of the product.

David Tsur, CEO of Kamada, said: “We are delighted to have formed this relationship with a US specialty products distributor. This is another strategic milestone for Kamada as we focus on bringing our products to the US and EU markets.

“The Biologics license Aapplication for AAT-IV for the treatment of alpha-1 antitrypsin deficiency was recently accepted for review by the FDA and a decision on its approval is expected in Q2 2010. Alpha-1 deficiency is a debilitating respiratory disease and we look forward to working with our experienced partner to deliver this product to patients as quickly as possible. We are also developing an inhaled version of AAT that has recently completed three separate phase II trials, and that we hope to add to our portfolio of specialty products in the coming years.”